T1	Intervention 533 616	Zidovudine was discontinued in group A patients before instituting GM-CSF treatment
T2	Intervention 672 774	Group B patients continued on full-dose (1,200 mg/d) zidovudine therapy while beginning GM-CSF therapy
T3	Intervention 1339 1413	patients were begun on subcutaneous GM-CSF at a dose of 1.0 microgram/kg/d
T4	Intervention 1444 1468	2 weeks of daily GM-CSF,
T5	Intervention 1855 1915	full-dose zidovudine concurrently with GM-CSF administration
